Cargando…

Interleukin-1 mediates Alzheimer and Lewy body pathologies

BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, W Sue T, Liu, Ling, Li, Yuekui, Mrak, Robert E, Barger, Steven W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435743/
https://www.ncbi.nlm.nih.gov/pubmed/16542445
http://dx.doi.org/10.1186/1742-2094-3-5
_version_ 1782127268386045952
author Griffin, W Sue T
Liu, Ling
Li, Yuekui
Mrak, Robert E
Barger, Steven W
author_facet Griffin, W Sue T
Liu, Ling
Li, Yuekui
Mrak, Robert E
Barger, Steven W
author_sort Griffin, W Sue T
collection PubMed
description BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid plaques, and neurofibrillary tangles (hyperphosphorylated tau aggregates). The co-occurrence of these clinical and neuropathological changes suggests shared pathogenic mechanisms in these diseases, previously assumed to be distinct. Glial activation, with overexpression of interleukin-1 (IL-1) and other proinflammatory cytokines, has been increasingly implicated in the pathogenesis of both AD and PD. METHODS: Rat primary cultures of microglia and cortical neurons were cultured either separately or as mixed cultures. Microglia or cocultures were treated with a secreted fragment (sAPPα) of the β-amyloid precursor protein (βAPP). Neurons were treated with IL-1β or conditioned medium from sAPPα-activated microglia, with or without IL-1 receptor antagonist. Slow-release pellets containing either IL-1β or bovine serum albumin (control) were implanted in cortex of rats, and mRNA for various neuropathological markers was analyzed by RT-PCR. Many of the same markers were assessed in tissue sections from human cases of AD/LBD. RESULTS: Activation of microglia with sAPPα resulted in a dose-dependent increase in secreted IL-1β. Cortical neurons treated with IL-1β showed a dose-dependent increase in sAPPα release, an effect that was enhanced in the presence of microglia. IL-1β also elevated the levels of α-synuclein, activated MAPK-p38, and phosphorylated tau; a concomitant decrease in levels of synaptophysin occurred. Delivery of IL-1β by slow-release pellets elevated mRNAs encoding α-synuclein, βAPP, tau, and MAPK-p38 compared to controls. Finally, human cases of AD/LBD showed colocalization of IL-1-expressing microglia with neurons that simultaneously overexpressed βAPP and contained both Lewy bodies and neurofibrillary tangles. CONCLUSION: Our findings suggest that IL-1 drives production of substrates necessary for formation of the major neuropathological changes characteristic of AD/LBD.
format Text
id pubmed-1435743
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14357432006-04-13 Interleukin-1 mediates Alzheimer and Lewy body pathologies Griffin, W Sue T Liu, Ling Li, Yuekui Mrak, Robert E Barger, Steven W J Neuroinflammation Research BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid plaques, and neurofibrillary tangles (hyperphosphorylated tau aggregates). The co-occurrence of these clinical and neuropathological changes suggests shared pathogenic mechanisms in these diseases, previously assumed to be distinct. Glial activation, with overexpression of interleukin-1 (IL-1) and other proinflammatory cytokines, has been increasingly implicated in the pathogenesis of both AD and PD. METHODS: Rat primary cultures of microglia and cortical neurons were cultured either separately or as mixed cultures. Microglia or cocultures were treated with a secreted fragment (sAPPα) of the β-amyloid precursor protein (βAPP). Neurons were treated with IL-1β or conditioned medium from sAPPα-activated microglia, with or without IL-1 receptor antagonist. Slow-release pellets containing either IL-1β or bovine serum albumin (control) were implanted in cortex of rats, and mRNA for various neuropathological markers was analyzed by RT-PCR. Many of the same markers were assessed in tissue sections from human cases of AD/LBD. RESULTS: Activation of microglia with sAPPα resulted in a dose-dependent increase in secreted IL-1β. Cortical neurons treated with IL-1β showed a dose-dependent increase in sAPPα release, an effect that was enhanced in the presence of microglia. IL-1β also elevated the levels of α-synuclein, activated MAPK-p38, and phosphorylated tau; a concomitant decrease in levels of synaptophysin occurred. Delivery of IL-1β by slow-release pellets elevated mRNAs encoding α-synuclein, βAPP, tau, and MAPK-p38 compared to controls. Finally, human cases of AD/LBD showed colocalization of IL-1-expressing microglia with neurons that simultaneously overexpressed βAPP and contained both Lewy bodies and neurofibrillary tangles. CONCLUSION: Our findings suggest that IL-1 drives production of substrates necessary for formation of the major neuropathological changes characteristic of AD/LBD. BioMed Central 2006-03-16 /pmc/articles/PMC1435743/ /pubmed/16542445 http://dx.doi.org/10.1186/1742-2094-3-5 Text en Copyright © 2006 Griffin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Griffin, W Sue T
Liu, Ling
Li, Yuekui
Mrak, Robert E
Barger, Steven W
Interleukin-1 mediates Alzheimer and Lewy body pathologies
title Interleukin-1 mediates Alzheimer and Lewy body pathologies
title_full Interleukin-1 mediates Alzheimer and Lewy body pathologies
title_fullStr Interleukin-1 mediates Alzheimer and Lewy body pathologies
title_full_unstemmed Interleukin-1 mediates Alzheimer and Lewy body pathologies
title_short Interleukin-1 mediates Alzheimer and Lewy body pathologies
title_sort interleukin-1 mediates alzheimer and lewy body pathologies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435743/
https://www.ncbi.nlm.nih.gov/pubmed/16542445
http://dx.doi.org/10.1186/1742-2094-3-5
work_keys_str_mv AT griffinwsuet interleukin1mediatesalzheimerandlewybodypathologies
AT liuling interleukin1mediatesalzheimerandlewybodypathologies
AT liyuekui interleukin1mediatesalzheimerandlewybodypathologies
AT mrakroberte interleukin1mediatesalzheimerandlewybodypathologies
AT bargerstevenw interleukin1mediatesalzheimerandlewybodypathologies